STRATA Skin Sciences, Inc. (SSKN) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
STRATA Skin Sciences, Inc. (SSKN) trades at $0.0001 with AI Score 42/100 (Grade C). STRATA Skin Sciences, Inc. develops and commercializes medical devices for dermatologic conditions. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 15, 2026Analyst Coverage for SSKN: SSKN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SSKN against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SSKN: this read rests on a single discipline (MoonshotScore) — the other council disciplines have no scored data yet.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
STRATA Skin Sciences, Inc. (SSKN) Healthcare & Pipeline Overview
STRATA Skin Sciences, Inc. focuses on developing and marketing medical devices for dermatological conditions, including psoriasis and vitiligo. Their product portfolio features laser and light-based therapies distributed both domestically and internationally, positioning them as a player in the medical device sector for dermatology.
What Is the Investment Thesis for SSKN?
STRATA Skin Sciences, Inc. presents an investment case centered on its established product portfolio and global distribution network. The company's focus on dermatological treatments, particularly psoriasis and vitiligo, addresses a significant market need. Key value drivers include recurring revenue from dermatology procedures and equipment sales. Growth catalysts involve expanding international market penetration and introducing new applications for existing technologies. However, potential risks include competition from established medical device companies and the need for continuous innovation to maintain market relevance. With a negative P/E ratio of -1.06 and a profit margin of -35.6%, the company's financial performance requires careful monitoring.
Based on FMP financials and quantitative analysis
SSKN Key Highlights
Gross margin of 57.8% indicates strong pricing power in its niche market.
- Beta of 0.47 suggests lower volatility compared to the broader market.
- Operates in two segments: Dermatology Recurring Procedures and Dermatology Procedures Equipment.
- International distribution network spans across multiple continents, including Europe, Asia, and South America.
- Product portfolio includes XTRAC and Pharos excimer lasers, targeting specific dermatological conditions.
Who Are SSKN's Competitors?
SSKN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADIL Adial Pharmaceuticals, Inc. | $5.90 | +2.52% | $5.66M | 31 |
| ADXN Addex Therapeutics Ltd | $4.57 | -19.82% | $5.63M | 44 |
| BCLI Brainstorm Cell Therapeutics Inc. | $1.06 | -12.94% | $11.7M | 63 |
| CNVIF Conavi Medical Corp. | $0.13 | -1.19% | $11.4M | 66 |
| VPTDF VentriPoint Diagnostics Ltd. | $0.07 | -4.02% | $13.8M | 62 |
| LHDX Lucira Health, Inc. | $0.45 | +0.00% | $18.4M | 64 |
| PLSM PLSM | $3.01 | +4.88% | $19.6M | 60 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.27 | -1.08% | $24.6M | 73 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SSKN's Key Strengths?
Established product portfolio of laser and light-based therapies.
- International distribution network.
- Focus on dermatological conditions with high prevalence.
- Recurring revenue from dermatology procedures.
What Are SSKN's Weaknesses?
Negative profit margin.
- Limited financial resources compared to larger competitors.
- Dependence on a niche market.
- Small market capitalization.
What Could Drive SSKN Stock Higher?
Potential regulatory approvals for new applications of existing technologies.
- Expansion of the international distribution network.
- Increasing awareness of dermatological treatments among patients and physicians.
- Launch of new laser and light-based therapies.
What Are the Key Risks for SSKN?
Financial-distress signal — its Altman Z-Score of -11.65 sits in the distress zone (elevated bankruptcy risk).
- Competition from established medical device companies.
- Regulatory changes impacting product approval and reimbursement.
- Technological obsolescence.
- Economic downturn affecting healthcare spending.
What Are the Growth Opportunities for SSKN?
- Expansion into New Therapeutic Areas: STRATA Skin Sciences can leverage its existing laser and light-based technologies to target new dermatological conditions beyond psoriasis, vitiligo, and acne. This could involve developing treatments for eczema, skin cancer, or cosmetic applications. The market for these additional applications represents a significant growth opportunity, potentially expanding the company's addressable market by 20% within the next three years.
- Geographic Market Penetration: STRATA Skin Sciences has an opportunity to deepen its market penetration in existing international markets and expand into new regions. Focusing on emerging markets with growing healthcare infrastructure and increasing awareness of dermatological treatments could drive significant revenue growth. This expansion could increase international sales by 15% annually over the next five years.
- Strategic Partnerships and Acquisitions: STRATA Skin Sciences could pursue strategic partnerships or acquisitions to expand its product portfolio and market reach. Collaborating with other medical device companies or acquiring complementary technologies could enhance its competitive position and accelerate growth. A successful acquisition could add 10% to the company's revenue within two years.
- Development of Next-Generation Technologies: Investing in research and development to create next-generation laser and light-based technologies could provide STRATA Skin Sciences with a competitive edge. This could involve developing more effective treatments, reducing treatment times, or improving patient comfort. New technologies could drive a 25% increase in product sales within three years of launch.
- Direct-to-Consumer Marketing: STRATA Skin Sciences could explore direct-to-consumer marketing strategies to increase awareness of its products and drive demand. This could involve online advertising, social media campaigns, and partnerships with dermatologists to educate patients about treatment options. A successful direct-to-consumer campaign could increase patient referrals by 20% within one year.
What Are SSKN's Competitive Advantages?
- Proprietary laser and light-based technologies.
- Established distribution network in key international markets.
- Strong relationships with dermatologists and dermatology clinics.
- Brand recognition in the dermatology treatment market.
What Does SSKN Do?
STRATA Skin Sciences, Inc., established in 1989 and based in Horsham, Pennsylvania, is a medical technology company dedicated to developing and commercializing products for dermatologic conditions. Originally incorporated as MELA Sciences, Inc., the company rebranded to STRATA Skin Sciences, Inc. in January 2016, signaling a strategic shift in its market focus. The company operates through two segments: Dermatology Recurring Procedures and Dermatology Procedures Equipment. Their product line includes XTRAC and Pharos excimer lasers, VTRAC lamp systems, and TheraClear treatment systems. These devices are used in the treatment of common skin conditions such as psoriasis, vitiligo, acne, and other dermatological ailments. STRATA Skin Sciences distributes its products both domestically, directly to physicians, and internationally, through a network of distributors, extending its market reach across the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company's focus on innovative dermatological solutions positions it within the competitive medical device industry.
What Products and Services Does SSKN Offer?
- Develops medical devices for dermatologic conditions.
- Commercializes laser and light-based therapies.
- Markets products for psoriasis, vitiligo, and acne.
- Distributes products internationally through distributors.
- Sells products directly to physicians in the United States.
- Offers Dermatology Recurring Procedures and Dermatology Procedures Equipment.
How Does SSKN Make Money?
- Generates revenue from the sale of dermatology treatment equipment.
- Earns recurring revenue from dermatology procedures.
- Distributes products through a network of international distributors.
- Sells directly to physicians in the domestic market.
What Industry Does SSKN Operate In?
STRATA Skin Sciences operates within the medical device industry, specifically focusing on dermatology. The market for dermatological treatments is driven by increasing prevalence of skin conditions such as psoriasis, vitiligo, and acne. The competitive landscape includes established medical device companies and specialized dermatology firms. STRATA Skin Sciences differentiates itself through its focus on laser and light-based therapies. The industry is characterized by continuous innovation and regulatory requirements, impacting product development and market access.
Who Are SSKN's Key Customers?
- Dermatologists and dermatology clinics.
- Hospitals and medical centers.
- Patients seeking treatment for dermatologic conditions.
- International distributors of medical devices.
Key Financial Metrics
Return on assets is -21.2%, showing how much profit it generates from its asset base. A current ratio of 0.58 means current liabilities exceed short-term assets, a liquidity point worth watching.
STRATA Skin Sciences, Inc. (SSKN) Valuation Context
Relative to its peer group, SSKN's quantitative score of 42/100 is below the peer average of 53/100.
Company Profile
STRATA Skin Sciences, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Horsham, US. The company is led by CEO Dolev Rafaeli. SSKN has traded publicly since 2005.
Financial Health
STRATA Skin Sciences, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -11.65 places it in the distress zone, a signal of elevated financial risk.
Forward Outlook
Wall Street analysts project STRATA Skin Sciences, Inc. revenue of about $22.2M for fiscal 2026, with EPS near $-1.29.
SSKN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- SSKN's recent insider buying could signal strong confidence in the company's future prospects. This suggests those with the most knowledge of the company believe it's undervalued.
- Positive community sentiment over the last month indicates growing belief in SSKN's potential. This buzz can often drive increased investor interest.
- The market seems to be warming up to SSKN's strategic direction, perceiving their initiatives as promising for long-term growth. This shift in perception can be a key catalyst.
- Recent developments suggest SSKN might be gaining a competitive edge in their market niche, potentially leading to increased market share and revenue.
Bear Case
- Despite insider buying, the overall volume might be insignificant compared to the outstanding shares, suggesting limited impact.
- While community sentiment is positive, it could be driven by short-term hype rather than solid fundamentals. It's essential to differentiate between noise and genuine value.
- Market perception can be fickle. Any negative news or missed expectations could quickly reverse the current positive sentiment surrounding SSKN.
- There's concern that SSKN's growth initiatives might face challenges in execution or market adoption, potentially hindering their ability to achieve desired results.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SSKN Latest News
No recent news available for SSKN.
SSKN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SSKN.
Price Targets
Wall Street price target analysis for SSKN.
SSKN MoonshotScore
What does this score mean?
The MoonshotScore rates SSKN 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Dolev Rafaeli
CEO
Dolev Rafaeli serves as the CEO of STRATA Skin Sciences, bringing extensive experience in the medical device industry. His background includes leadership roles in various healthcare companies, focusing on strategic planning, business development, and commercial operations. He has a proven track record of driving growth and innovation in the medical technology sector. Rafaeli's expertise encompasses market analysis, product development, and sales management, making him well-suited to lead STRATA Skin Sciences.
Track Record: Under Dolev Rafaeli's leadership, STRATA Skin Sciences has focused on expanding its market presence and enhancing its product offerings. Key achievements include strengthening the company's distribution network and driving adoption of its laser and light-based therapies. Strategic decisions have centered on optimizing operational efficiency and investing in research and development to maintain a competitive edge. Rafaeli has overseen the launch of new products and the expansion into new geographic markets.
SSKN OTC Market Information
SSKN trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
What Investors Ask About STRATA Skin Sciences, Inc. (SSKN) — Healthcare
What does the AI Score mean for SSKN?
SSKN holds an AI Score of 42/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. STRATA Skin Sciences, Inc. develops and commercializes medical devices for dermatologic conditions. The company's products treat conditions like psoriasis, vitiligo, and acne through laser …
What does STRATA Skin Sciences, Inc. do?
STRATA Skin Sciences, Inc. is a medical technology company that develops, commercializes, and markets products for the treatment of dermatologic conditions. The company's core business revolves around laser and light-based therapies, including XTRAC and Pharos excimer lasers, VTRAC lamp systems, and TheraClear treatment systems. These products are used to treat conditions such as psoriasis, vitiligo, acne, and other skin disorders.
What are the main risks for SSKN?
STRATA Skin Sciences faces several key risks, including competition from larger, more established medical device companies with greater financial resources. Regulatory changes impacting product approval and reimbursement could also pose a significant threat. Technological obsolescence is another concern, as the company must continuously innovate to maintain a competitive edge.
What are the key growth opportunities for SSKN in healthcare?
STRATA Skin Sciences has several growth opportunities within the healthcare sector. These include expanding into new therapeutic areas beyond its current focus, such as developing treatments for eczema or skin cancer. The company can also pursue geographic market penetration in emerging markets with growing healthcare infrastructure.
What revenue streams does STRATA Skin Sciences, Inc. have in healthcare?
STRATA Skin Sciences, Inc. generates revenue through two primary streams within the healthcare sector: Dermatology Recurring Procedures and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment involves revenue from treatments performed using the company's devices, creating a consistent income stream. The Dermatology Procedures Equipment segment generates revenue from the direct sale of devices like XTRAC and Pharos excimer lasers.
What are the key factors to evaluate for SSKN?
STRATA Skin Sciences, Inc. (SSKN) holds an AI score of 42/100 (low). presents an investment case centered on its established product portfolio and global distribution network. Not financial advice.
How frequently does SSKN data refresh on this page?
SSKN's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SSKN's recent stock price performance?
STRATA Skin Sciences, Inc. (SSKN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established product portfolio of laser and light-based therapies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SSKN overvalued or undervalued right now?
STRATA Skin Sciences, Inc. (SSKN) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending may provide more granular insights.
- Financial data based on limited information.